Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at Piper Sandler

Piper Sandler began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report issued on Monday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Piper Sandler’s price objective points to a potential upside of 26.40% from the company’s current price.

A number of other analysts also recently issued reports on the company. Baird R W raised Beta Bionics to a “hold” rating in a research note on Thursday. Robert W. Baird assumed coverage on shares of Beta Bionics in a research report on Thursday. They set a “neutral” rating and a $20.00 price target on the stock. LADENBURG THALM/SH SH initiated coverage on Beta Bionics in a research report on Thursday. They issued a “neutral” rating and a $20.00 price objective for the company. Finally, Leerink Partners began coverage on Beta Bionics in a research note on Monday. They issued an “outperform” rating and a $28.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus price target of $23.80.

Beta Bionics Trading Down 1.4 %

BBNX opened at $20.57 on Monday. Beta Bionics has a 52-week low of $20.57 and a 52-week high of $24.50.

Insiders Place Their Bets

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mike Mensinger acquired 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the purchase, the insider now owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.